Outside of Treatment in Metastatic Breast Cancer

Nine years of Pinktober while living with metastatic breast cancer.

Christina McAmis’ cancer journey began when she found a lump while breastfeeding. The attorney and mother of three tells the “Cancer Horizons” podcast what the last nine years have been like for her and her family.

Patients with HER2-positive metastatic breast cancer may receive sufficient first-line treatment with Perjeta plus Herceptin without chemotherapy.

A patient with metastatic breast cancer shares how she learned that her disease was recently reclassified as HER-2 low, and what it was like to first learn about the FDA-approved drug years before she would be prescribed the treatment.

Genetic testing is the norm for cancer patients with familial history. How did I let it slip through the crack?

The application for capivasertib plus Faslodex in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer has also been granted priority review, meaning that the FDA has six months to make a decision.